Business Combination, Assets Acquired, Measurement Input

No definition available.

Name:	ew_BusinessCombinationAssetsAcquiredMeasurementInput
Namespace Prefix:	ew_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, In-process Research and Development, Expected Costs

+ References

No definition available.

+ Details

Name:	ew_BusinessCombinationInprocessResearchandDevelopmentExpectedCosts
Namespace Prefix:	ew_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of voting equity interests acquired at the acquisition date in the business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479328/805-10-50-2

+ Details

Name:	us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 928
-SubTopic 340
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483147/928-340-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ew_MedicalTechnologyCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ew_HarpoonMedicalInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ew_CardiAQValveTechnologiesInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

BUSINESS COMBINATIONS - Narrative (Details) - USD ($)	1 Months Ended	12 Months Ended
BUSINESS COMBINATIONS - Narrative (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2021	Feb. 28, 2023	Dec. 31, 2022	Jul. 03, 2015
Business Acquisition [Line Items]
Developed technology		$ 329,200,000			$ 345,800,000
In-process Research and Development
Business Acquisition [Line Items]
Impairment charges		0	$ 0
Developed technology
Business Acquisition [Line Items]
Developed technology		197,600,000			$ 128,100,000
Medical Technology Company
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction				$ 68,600,000
Medical Technology Company \| Measurement Input, Discount Rate
Business Acquisition [Line Items]
Percentage of discount rate				13.00%
Medical Technology Company \| Variable Interest Entity, Primary Beneficiary
Business Acquisition [Line Items]
Percentage of interest acquired				61.00%
Harpoon Medical \| In-process Research and Development
Business Acquisition [Line Items]
Impairment charges	$ 28,100,000
CardiAQ
Business Acquisition [Line Items]
Additional research and development expenditures to be incurred prior to product introduction						$ 97,700,000
CardiAQ \| Developed technology
Business Acquisition [Line Items]
Developed technology		$ 69,000,000